Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Triple-Negative Breast Carcinoma”

152 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 152 results

Large-scale testing (Phase 3)Study completedNCT01216111
What this trial is testing

Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

Who this might be right for
Triple Negative Breast Cancer
Fudan University 647
Early research (Phase 1)Ended earlyNCT01071564
What this trial is testing

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+5 more
National Cancer Institute (NCI) 13
Testing effectiveness (Phase 2)Ended earlyNCT02003092
What this trial is testing

RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

Who this might be right for
Solid TumorTriple Negative Breast Cancer
Rexahn Pharmaceuticals, Inc. 18
Early research (Phase 1)Study completedNCT01623349
What this trial is testing

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Who this might be right for
Ovarian CancerBreast Cancer
Dana-Farber Cancer Institute 118
Large-scale testing (Phase 3)Looking for participantsNCT06081244
What this trial is testing

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Who this might be right for
Triple Negative Breast Cancer
West German Study Group 348
Testing effectiveness (Phase 2)UnknownNCT03544723
What this trial is testing

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Who this might be right for
Solid TumorLymphoma
MultiVir, Inc. 40
Not applicableWithdrawnNCT01292083
What this trial is testing

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

Who this might be right for
Recurrent Breast CancerStage IA Breast CancerStage IB Breast Cancer+6 more
University of Southern California
Large-scale testing (Phase 3)UnknownNCT02207335
What this trial is testing

Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 120
Early research (Phase 1)Looking for participantsNCT06347068
What this trial is testing

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Who this might be right for
Breast CancerRelapseResistant Cancer+1 more
UNC Lineberger Comprehensive Cancer Center 42
Early research (Phase 1)Study completedNCT02672475
What this trial is testing

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+3 more
Vanderbilt-Ingram Cancer Center 29
Early research (Phase 1)Study completedNCT01145430
What this trial is testing

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMale Breast Carcinoma+7 more
National Cancer Institute (NCI) 45
Large-scale testing (Phase 3)Active Not RecruitingNCT05347134
What this trial is testing

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 254
Testing effectiveness (Phase 2)Study completedNCT03394027
What this trial is testing

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Who this might be right for
Triple Negative Breast CancerEndometrial CancerHormone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Study completedNCT02041429
What this trial is testing

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

Who this might be right for
Recurrent Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03012100
What this trial is testing

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Bilateral Breast CarcinomaBreast Inflammatory CarcinomaStage IB Breast Cancer AJCC v7+9 more
Academic and Community Cancer Research United 280
Large-scale testing (Phase 3)Study completedNCT02819518
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Merck Sharp & Dohme LLC 882
Early research (Phase 1)Active Not RecruitingNCT05537740
What this trial is testing

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bayer 129
Testing effectiveness (Phase 2)Active Not RecruitingNCT02484404
What this trial is testing

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Who this might be right for
Colorectal NeoplasmsBreast Neoplasms
National Cancer Institute (NCI) 268
Testing effectiveness (Phase 2)Study completedNCT02632448
What this trial is testing

LY2880070 in Participants With Advanced or Metastatic Cancer

Who this might be right for
Solid TumorsColorectal CancerBreast Cancer+9 more
Esperas Pharma Inc. 229
Early research (Phase 1)Study completedNCT02309177
What this trial is testing

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsPancreatic Neoplasms
Celgene 114
Load More Results